Reference Number: 16122474
Release Date: January 17, 2017
To qualify for a waiver to treat patients with OUD, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician (physician must be waivered) to prescribe medications for the treatment of OUD
Please ensure that your state regulations allow you to prescribe Buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.
Completing this Activity
Once you have REGISTERED this course in the AANP CE Center, under Download Materials, review the instructions provided for completing this activity on the Partner site.
- Participants must complete, in full, both parts of this educational requirement to be waivered (see below)
- 8-Hour Training: Part I: The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements
- 16-Hour Training: Part II: NP/PA 16-Hour Waiver Training
- Learners will be directed to a partner site for content, and re-directed back to the AANP CE Center to complete the requirements for CE and obtain the CE Certificate. Learners must log on in the Partner site and and Register this course on their site to continue.
- A participation code will be provided at the end of the CE activity's content. See Instructions for details.
- Those who complete this educational activity must allow approximately a week for their information to be reported to Center for Substance Abuse Treatment (CSAT). They will then be able to apply for the waiver to prescribe buprenorphine to their patients with opioid use disorders.
- Monitor the SAMHSA website regarding the NP waiver application form: The information regarding the application process will come from the Substance Abuse and Mental Health Services Administration (SAMHSA). SAMHSA has stated their plans to open the application process for NPs/PAs in early 2017. Updates on the waiver application will be available at http://www.samhsa.gov/medication-assisted-treatment.
- NOTE: CARA also defers to state law regarding whether an NP or PA works with a physician through a supervisory or collaborative relationship and, where this applies, the physician must also be waivered to prescribe buprenorphine.
This CE activity provides two training sessions that must be completed to fulfill the 24-hour continuing education training requirements outlined in the Comprehensive Addiction and Recovery Act (CARA). Participants must complete both activities to qualify for the waiver application. Those who complete this educational activity must allow a week for their information to be reported and then will be able to apply for the waiver to prescribe buprenorphine for patients with opioid addiction.
ASAM, AANP and AAPA have formed a collaborative to provide the 24-hour waiver training for nurse practitioners and physician assistants. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).
8-hour Activity Overview: Part I: The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements - will ensure that participants are exposed to the highest quality, evidence-based practices when using buprenorphine to treat opioid use disorders.
16-hour Activity Overview: Part II: NP/PA 16-Hour Waiver Training - The 16-hour product developed includes all additional education required by the Comprehensive Addiction and Recovery Act (CARA) for nurse practitioners to successfully apply for a waiver to prescribe buprenorphine for office-based treatment of opioid use disorders.
At the completion of this presentation Learners will be able to:
- Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
- Identify and assess patients who are appropriate for treatment with medications
- Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
- Discuss the psychiatric and medical co-morbidities associated with opioid addiction
Content Developers and Speakers
- Daniel P. Alford, MD, MPH, FACP, DFASAM
- Sarah Bagley, MD
- Jeffrey Baxter, MD
- Adam Bisaga, MD
- Timothy K. Brennan, MD, MPH
- Theordore Cicero, PhD
- Captain Jennifer Fan, PharmD, JD
- James W. Finch, MD, DFASAM
- Debra Houry, MD, MPH
- Brian Hurley, MD, MBA, DFASAM
- Magaret A. Jarvis, MD, DFASAM
- Karol Kaltenbach, PhD
- Kyle Kampman, MD
- Colleen Labelle, BSN, RN-BC, CARN
- Lorenzo Leggio, MD, PhD, MSc
- Sharon Levy, MD, MPH
- Raye Z. Litten, PhD,
- Paula Lum, MD, MPH, FASAM
- Barbara Mason, PhD
- David Mee-Lee, MD, FASAM
- Yngvild K. Olsen, MD, MPH, FASAM
- Ricardo Restrepo, MD, MPH,
- Richard N. Rosenthal, MD, FASAM
- Kelley Saia, MD
- Edwin A. Salsitz, MD, DFASAM
- Andrew Saxon, MD, FASAM
- Mark Sullivan, MD, PhD,
- Frank J. Vocci, PhD,
- R. Corey Waller, MD, MS, DFASAM,
- Alexander Y. Walley, MD, MSc, FASAM,
- Timothy J. Weigand, MD, DABAM, FACMT, FAACT
- Tricia Wright, MD, MS, FACOG, FASAM
- Tricia E. Wright, MD, MS, FACOD, FASAM
- Stephen A. Wyatt, DO, FASAM
This activity was planned in accordance with AANP Accreditation Standards and Policies in collaboration with ASAM, and AAPA to provide the 24 hours of required education. Planner, faculty, and all other relevant disclosures are listed on the ASAM website.
The collaborative of ASAM, AANP and AAPA identified and reviewed this content to provide the NP/PA training required by CARA. The NP/PA 24-Hour Waiver Training is available for free through 2017 in part by an unrestricted educational grant from Indivior.
This educational activity may contain opinions of the speakers from their personal experience. The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
To complete the CE for this activity, successfully complete all content and posttests on the partner site, and then submit the online program evaluation in the AANP CE Center.
For questions about this online CE activity, or more information concerning the AANP CE Center, contact the AANP CE Center Manager at CECenter@aanp.org.